Skip to Content
Merck
  • Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.

Clinical cancer research : an official journal of the American Association for Cancer Research (2016-06-12)
Michele Cea, Antonia Cagnetta, Chirag Acharya, Prakrati Acharya, Yu-Tzu Tai, Cao Yang, Davide Lovera, Debora Soncini, Maurizio Miglino, Giulio Fraternali-Orcioni, Luca Mastracci, Alessio Nencioni, Fabrizio Montecucco, Fiammetta Monacelli, Alberto Ballestrero, Teru Hideshima, Dharminder Chauhan, Marco Gobbi, Roberto M Lemoli, Nikhil Munshi, Steven P Treon, Kenneth C Anderson
ABSTRACT

Nicotinamide phosphoribosyltransferase (Nampt) regulates intracellular NAD We investigated Nampt role in MW cells using both mRNA and protein expression analyses. We have also used loss-of-function approaches to investigate the growth and survival effects of Nampt on MW cells and further tested the anti-MW activity of dual Nampt and BTK inhibition in vitro and in vivo RESULTS: We found that Waldenström macroglobulinemia cells exhibit high levels of Nampt compared with normal B cells. Loss of function studies suggested a potential oncogenic role of Nampt in Waldenström macroglobulinemia cells, and BTK-inhibitor ibrutinib and FK866 resulted in a significant and synergistic anti-Waldenström macroglobulinemia cell death, regardless of MYD88 and CXCR4 mutational status. Cell death was associated with: (i) activation of caspase-3, PARP and downregulation of Mcl-1, (ii) enhanced intracellular ATP and NAD Our results show intracellular NAD

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human MYD88